BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice protein BPC. With over 100 published peer-reviewed studies examining its biology across gastrointestinal, musculoskeletal, neurological, and vascular research contexts, BPC-157 is one of the most extensively characterised tissue biology research peptides available.

The exceptional protease stability of BPC-157 in biological media — far exceeding most 15-residue peptides — is attributable to the Pro-Pro-Pro sequence at positions 3-5. These three consecutive proline residues form a polyproline II (PPII) helix: a rigid, left-handed helical conformation with unusual surface chemistry. The absence of backbone NH groups (proline's pyrrolidine ring eliminates these hydrogen bond donors) and the unique spatial arrangement of the PPII surface prevents most endopeptidases from engaging productive substrate binding. This inherent protease resistance is a key practical advantage enabling BPC-157 research in complex biological matrices including plasma, gastric fluid, and serum-containing cell culture media.

BPC-157's mechanistic research profile encompasses four interconnected molecular pathways. The nitric oxide/eNOS axis is most extensively published: research has examined eNOS expression changes, phosphorylation at the activating Ser1177 site (Akt-mediated) and the inhibitory Thr495 site, and downstream NO production in endothelial and smooth muscle cell models. Published studies using L-NAME (NOS inhibitor) alongside BPC-157 have characterised the proportion of effects that are NOS-dependent versus NOS-independent, revealing both mechanisms contribute.

The VEGF/EGR-1 angiogenic axis represents the second major research theme. Early growth response protein 1 (EGR-1) is a zinc finger transcription factor driving VEGF gene expression. VEGF activates VEGFR2 on endothelial cells, triggering downstream PI3K/Akt, MAPK/ERK, and PLCgamma cascades that drive endothelial cell proliferation, directional migration, and capillary tube formation. Research endpoints examining BPC-157 in this context include EGR-1 promoter-luciferase reporter assays, VEGF secretion measurement by ELISA in conditioned medium, and Matrigel tube formation assays.

The FAK-paxillin pathway connects BPC-157 to cell adhesion, migration, and cytoskeletal biology. FAK (focal adhesion kinase) autophosphorylation at Tyr397 creates a Src kinase docking site, initiating downstream phosphorylation of paxillin at Tyr118, vinculin, and other focal adhesion complex proteins. Published tendon fibroblast research has implicated FAK-paxillin signalling in BPC-157's effects on tendon outgrowth and cell migration in scratch assay models.

The fourth research dimension is neurochemical: published studies have examined BPC-157 in the context of dopaminergic system modulation (dopamine transporter expression, D1/D2 receptor sensitivity in striatal models) and serotonergic pathway interactions. These neurochemical research directions connect BPC-157 to the well-established gastrointestinal-brain axis, given the gut's extensive serotonergic biology and the peptide's gastric origin.

Gastrointestinal cytoprotection research using BPC-157 examines mucosal blood flow preservation via eNOS/NO, epithelial barrier integrity (TEER measurement in Caco-2 monolayers), and mucosal healing in models of gastric, intestinal, and colonic injury.

MW: 1419.56 g/mol. CAS: 137525-51-0. Molecular formula: C62H98N16O22. Reconstitute in bacteriostatic water at 1mg/mL. Stable lyophilised at -20°C for 2+ years. For laboratory and analytical research purposes only.

Research assay selection: scratch assay (cell migration, endpoint 24-48h) and Matrigel tube formation (angiogenesis, endpoint 4-8h) are the most commonly used BPC-157 cell-based assays. For NOS-dependence testing, pre-incubate cells with L-NAME (1mM) 30 minutes before BPC-157 addition. For VEGF-dependence, use anti-VEGF neutralising antibody in conditioned medium transfer experiments. Reconstitute in bacteriostatic water at 1mg/mL. MW: 1419.56 g/mol. CAS: 137525-51-0. Stable lyophilised at -20°C for 2+ years. Reconstituted solutions stable at 4°C for 2-3 weeks, at -20°C for 3 months. For laboratory and analytical research purposes only.